Recombinant bacillus calmette guerin vaccine for toxoplamasis and preparation method thereof

Abstract

The invention provides a recombinant bacillus calmette guerin (BCG) vaccine for toxoplamasis and a preparation method thereof. The preparation method for the recombinant bacillus calmette guerin vaccine comprises the following steps of: performing target (TA) cloning on an obtained toxoplasma gondii cyclophilin gene; sequencing and identifying correctly, performing enzyme cutting and recovering target fragments; connecting the target fragments with an Escherichia coli-mycobacterium shuttle expression vector pMV261 and an integrated expression vector pMV361 which are subjected to enzyme cutting reaction respectively; and converting recombinant plasmids to BCG, and screening by resistance and polymerase chain reaction (PCR) to obtain the recombinant bacillus calmette guerin vaccine for the positive toxoplasma gondii. The vaccine is high in heat stability and easy to transport, store and produce, is not needed to be purified and can be directly used for immune protection tests, and a complex process of protein aftertreatment is avoided, so the cost is reduced greatly, and the recombinant bacillus calmette guerin vaccine is suitable for vast rural areas.

Description

technical field [0001] The invention provides a recombinant BCG vaccine for toxoplasma gondii, which is used for the prevention and treatment of toxoplasmosis. The invention also provides a preparation method of the vaccine, which belongs to the technical field of vaccine preparation. Background technique [0002] Toxoplasmosis (Toxoplasmosis) is caused by Toxoplasma gondii, a worldwide widespread zoonotic disease, because of its wide range of hosts, it can infect humans and most animals. Toxoplasma gondii infection is a serious hazard to animal husbandry production, mainly causing miscarriage, teratogenicity, stillbirth and so on. The harm of Toxoplasma gondii is huge, but the prevention and treatment of this disease has not yet found an ideal drug. Although antiparasitic drugs are highly effective, cheap and easy to administer, the emergence of drug resistance in Toxoplasma gondii and the general concern of drug residues are increasing. In comparison, vaccines are relati...

AI Technical Summary

Problems solved by technology

The research on Toxoplasma gondii vaccines has gone through various explorations such as inactivated vaccines and live attenuated vaccines. The former stimulates the body to produce weak anti-infection ability, while the latter can produce a better protective effect, but due to the recovery of virulence after mutation, Therefore, it is not applicable to human beings. Therefore, it is the task of the present invention to adopt a genetic engineering method to develop a kind of efficient and cheap novel toxoplasma vaccine

Images